Table 1 Characteristics of the 915 patients with RA and their association with response to MTX.
Characteristic | Value | P ΔDAS28 a | P NR b |
|---|---|---|---|
Women, N (%) | 738 (80.6) | 0.002 | ns |
Age at treatment, mean ± SD | 52.7 ± 13.7 | <10−5 | 0.0003 |
RF positive, N (%) | 555 (60.6) | ns | ns |
Anti-CCP positivec, N (%) | 501 (54.7) | 0.001 | 0.03 |
Seropositivity (RF or antiCCP) | 682 (74.5) | 0.002 | ns |
Erosive arthritis, N (%) | 479 (52.3) | <10−6 | <10−5 |
Smoking habitc, N (%) | 195 (21.3) | ns | 0.003 |
Previous DMARD, N (%) | 185 (20.2) | <10−6 | <10−5 |
MTX maximum dosec, mean ± SD | 18.7 ± 4.6 | ns | ns |
Concomitant treatment | |||
Corticosteroids, N (%) | 660 (72.1) | 0.01 | 0.01 |
NSAIDsc, N (%) | 490 (53.5) | 0.0004 | <10−5 |
Baseline DAS28, mean ± SD | 5.3 ± 1.2 | <10−6 | <10−4 |
DAS28 at 6 months, mean ± SD | 4.0 ± 1.5 | ||
EULAR response at 6 months, N (%) | |||
Good responder | 250 (27.3) | ||
Moderate responder | 354 (38.7) | ||
Non-responder | 311 (34.0) | ||
